JP2016527225A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016527225A5 JP2016527225A5 JP2016526580A JP2016526580A JP2016527225A5 JP 2016527225 A5 JP2016527225 A5 JP 2016527225A5 JP 2016526580 A JP2016526580 A JP 2016526580A JP 2016526580 A JP2016526580 A JP 2016526580A JP 2016527225 A5 JP2016527225 A5 JP 2016527225A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- kabat
- seq
- upa
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 34
- 239000000427 antigen Substances 0.000 claims 18
- 102000036639 antigens Human genes 0.000 claims 18
- 108091007433 antigens Proteins 0.000 claims 18
- 125000000539 amino acid group Chemical group 0.000 claims 17
- 239000012634 fragment Substances 0.000 claims 17
- 101000638886 Homo sapiens Urokinase-type plasminogen activator Proteins 0.000 claims 11
- 150000001413 amino acids Chemical class 0.000 claims 8
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 6
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims 6
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 4
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims 4
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 4
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 230000004913 activation Effects 0.000 claims 3
- 230000002797 proteolythic effect Effects 0.000 claims 3
- 241000282567 Macaca fascicularis Species 0.000 claims 2
- 230000008878 coupling Effects 0.000 claims 2
- 238000010168 coupling process Methods 0.000 claims 2
- 238000005859 coupling reaction Methods 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 230000006020 chronic inflammation Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13176519.0 | 2013-07-15 | ||
| EP13176519 | 2013-07-15 | ||
| US201361847664P | 2013-07-18 | 2013-07-18 | |
| US61/847,664 | 2013-07-18 | ||
| PCT/EP2014/065136 WO2015007727A1 (en) | 2013-07-15 | 2014-07-15 | Antibodies that bind urokinase plasminogen activator |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016527225A JP2016527225A (ja) | 2016-09-08 |
| JP2016527225A5 true JP2016527225A5 (enExample) | 2017-08-10 |
Family
ID=48783103
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016526580A Withdrawn JP2016527225A (ja) | 2013-07-15 | 2014-07-15 | ウロキナーゼ型プラスミノーゲン活性化因子に結合する抗体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9908944B2 (enExample) |
| EP (1) | EP3022229A1 (enExample) |
| JP (1) | JP2016527225A (enExample) |
| CN (1) | CN105612183A (enExample) |
| TW (1) | TW201536810A (enExample) |
| WO (1) | WO2015007727A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201510758D0 (en) | 2015-06-18 | 2015-08-05 | Ucb Biopharma Sprl | Novel TNFa structure for use in therapy |
| GB201621907D0 (en) | 2016-12-21 | 2017-02-01 | Ucb Biopharma Sprl And Sanofi | Antibody epitope |
| CN110944651A (zh) | 2017-02-08 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途 |
| EP4273258A3 (en) | 2017-02-20 | 2024-01-17 | Dragonfly Therapeutics, Inc. | Proteins binding her2, nkg2d and cd16 |
| EP3459974B1 (en) * | 2017-09-21 | 2025-02-19 | Guy L. Reed | Specific plasmin inactivation by anticatalytic antibody |
| CA3090244A1 (en) * | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| MX2020008333A (es) | 2018-02-08 | 2020-09-21 | Dragonfly Therapeutics Inc | Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales. |
| CN112119093A (zh) | 2018-02-20 | 2020-12-22 | 蜻蜓治疗公司 | 结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法 |
| CA3108427A1 (en) | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| CN113164570B (zh) | 2018-08-08 | 2024-05-14 | 蜻蜓疗法股份有限公司 | 结合nkg2d、cd16和肿瘤相关抗原的蛋白质 |
| EA202091888A1 (ru) * | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| WO2020063823A1 (en) * | 2018-09-27 | 2020-04-02 | Zai Lab (Shanghai) Co., Ltd. | Anti-pd-1 antibodies and uses thereof |
| CN110343665B (zh) * | 2019-05-05 | 2023-07-14 | 吉林大学 | 一种car-t细胞及其应用 |
| CA3158174A1 (en) | 2019-10-28 | 2021-05-06 | Monash University | Antibodies for binding plasmin |
| AU2021268340A1 (en) | 2020-05-06 | 2022-12-08 | Dragonfly Therapeutics, Inc. | Proteins binding NKG2D, CD16 and CLEC12A |
| WO2022171196A1 (zh) * | 2021-02-11 | 2022-08-18 | 兰州大学第二医院 | 抗cd87抗体及其特异性嵌合抗原受体 |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| TW202606662A (zh) | 2024-04-26 | 2026-02-16 | 美商美國禮來大藥廠 | 蛋白質酪胺酸激酶7抗體及抗體藥物結合物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5453269A (en) | 1986-04-14 | 1995-09-26 | The General Hospital Corporation | Heterobifunctional antibodies having dual specificity for fibrin and thrombolylic agents and methods of use |
| TW212184B (enExample) | 1990-04-02 | 1993-09-01 | Takeda Pharm Industry Co Ltd | |
| US8062637B2 (en) | 2000-05-08 | 2011-11-22 | Morphosys Ag | Methods of ameliorating inflammatory disease using an uPA antagonist |
| EP1406652A2 (en) * | 2001-07-10 | 2004-04-14 | Omnio AB | Novel drug targets for arthritis |
| AU2002362197A1 (en) * | 2001-12-28 | 2003-07-24 | Chugai Seiyaku Kabushiki Kaisha | Method of stabilizing protein |
| WO2005048822A2 (en) | 2003-11-18 | 2005-06-02 | Attenuon Llc | Antibodies and/or conjugates thereof which bind to the amino terminal fragment of urokinase, compositions and uses thereof |
| WO2006050177A2 (en) | 2004-10-29 | 2006-05-11 | The Regents Of The University Of Colorado | Antibodies that bind urokinase-type plasminogen activator and epitopes therefor |
| EP2824183B1 (en) * | 2005-04-08 | 2020-07-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing bispecific antibodies |
| JP5908972B2 (ja) * | 2011-04-07 | 2016-04-26 | アムジエン・インコーポレーテツド | 新規な抗原結合タンパク質 |
-
2014
- 2014-07-15 TW TW103124237A patent/TW201536810A/zh unknown
- 2014-07-15 WO PCT/EP2014/065136 patent/WO2015007727A1/en not_active Ceased
- 2014-07-15 US US14/905,409 patent/US9908944B2/en not_active Expired - Fee Related
- 2014-07-15 CN CN201480040491.0A patent/CN105612183A/zh not_active Withdrawn
- 2014-07-15 EP EP14739165.0A patent/EP3022229A1/en not_active Withdrawn
- 2014-07-15 JP JP2016526580A patent/JP2016527225A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021514973A5 (enExample) | ||
| JP2024056687A5 (enExample) | ||
| JP2019122405A5 (enExample) | ||
| RU2017114341A (ru) | Антитела к pd-l1, связывающие pd-l1 собаки | |
| JP2016512551A5 (enExample) | ||
| HRP20201928T1 (hr) | Kombinirana terapija bispecifičnom antigen vezujućom molekulom koja aktivira t-stanice, za cd3 i folatni receptor 1 (folr1), i antagonistom vezivanja osi pd-1 | |
| JP2017528476A5 (enExample) | ||
| JP2010536384A5 (enExample) | ||
| PH12020551173A1 (en) | Anti-pd-l1 antibodies and uses thereof | |
| PE20181051A1 (es) | Anticuerpo anti-epha4 | |
| JP2013198490A5 (enExample) | ||
| RU2017137010A (ru) | Анти-сеасам6 антитела и их применения | |
| JP2013091655A5 (enExample) | ||
| NZ585559A (en) | Humanized antibodies against tl1a | |
| PE20141186A1 (es) | Proteinas de union al tnf-alfa | |
| JP2017534577A5 (enExample) | ||
| RU2017134495A (ru) | Антитела к альфа-рецептору собачьего интерлейкина-4 | |
| JP2018527903A5 (enExample) | ||
| JP2017052784A5 (enExample) | ||
| AR065506A1 (es) | Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades | |
| WO2006103100A3 (en) | Antibodies against ccr5 and uses thereof | |
| JP2014512809A5 (enExample) | ||
| NZ597996A (en) | Antibodies against human respiratory syncytial virus (rsv) and methods of use | |
| JP2016533763A5 (ja) | ヒトｐｄ−１に特異的に結合する抗体抗原結合ドメインおよびそれを含む医薬組成物 | |
| HRP20241013T1 (hr) | Protutijela za kelatirane radionuklide |